RPG Life SciencesNSE:RPGLIFE +2.62%92 Quick Ratio is 2.71 as of Mar. 2026, which is 82% above its 10-year median of 1.49. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,364.21 (Fairly Valued). The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, RPG Life Sciences ranks better than 73.19% on this metric.
RPG Life Sciences has a quick ratio of 2.71. It generally indicates good short-term financial strength.
The historical rank and industry rank for RPG Life Sciences's Quick Ratio or its related term are showing as below:
NSE:RPGLIFE'
s Quick Ratio Range Over the Past 10 Years
Min: 0.64 Med: 1.49 Max: 3.11
Current: 2.71
During the past 13 years, RPG Life Sciences's highest Quick Ratio was 3.11. The lowest was 0.64. And the median was 1.49.
NSE:RPGLIFE's Quick Ratio is ranked better than 73.19% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:RPGLIFE: 2.71
RPG Life Sciences (NSE:RPGLIFE) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
RPG Life Sciences Quick Ratio Related Terms
RPG Life Sciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
RPG Life Sciences's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a Quick Ratio of 2.71 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RPG Life Sciences and its competitors. This is 82% above median its historical median of 1.49. Over the past decade, RPG Life Sciences' Quick Ratio has ranged from 0.64 to 3.11. According to the industry distribution chart, RPG Life Sciences ranks #267 out of 996 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is RPG Life Sciences' Quick Ratio too high?
RPG Life Sciences' current Quick Ratio of 2.71 is 82% above median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 3.11. The Drug Manufacturers industry median Quick Ratio is 1.45. RPG Life Sciences' value of 2.71 is 86.9% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #267 out of 996 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #267 out of 996 companies for Quick Ratio. This puts RPG Life Sciences in the upper half of its industry. The industry median Quick Ratio is 1.45. RPG Life Sciences' value of 2.71 is 86.9% above this benchmark. Historically, RPG Life Sciences' own Quick Ratio has ranged from 0.64 to 3.11 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 1.45, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Quick Ratio of 2.71 is 86.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Quick Ratio is 2.71, which is 82% above median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,364.21, compared to a current price of ₹2,393.70 — trading 1.2% above its estimated fair value. The current Quick Ratio is 2.71, which is 82% above median its 10-year median of 1.49 and 86.9% above the Drug Manufacturers industry median of 1.45. RPG Life Sciences' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Quick Ratio is 2.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,393.70 is trading 1.2% above its estimated GF Value™ of ₹2,364.21.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
Quick Ratio: 2.71 (82% above median its 10-year median of 1.49)
GF Value™: ₹2,364.21 vs. price of ₹2,393.70 (1.2% above fair value)
Industry Position: 86.9% above the Drug Manufacturers median (#267 of 996)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score
Get the complete analysis for NSE:RPGLIFE
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
